Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas by unknown
BioMed CentralMolecular Cancer
ssOpen AcceResearch
Constitutive overexpression of a novel 21 kDa protein by Hodgkin 
Lymphoma and Aggressive Non-Hodgkin Lymphomas
Minglong Zhou1, Faisal M Fadlelmola1, Jason B Cohn2, Brian Skinnider1,3, 
Randy D Gascoyne1,3 and Diponkar Banerjee*1,3
Address: 1Centre for Translational and Applied Genomics (CTAG), Department of Pathology and Laboratory Medicine, British Columbia Cancer 
Agency, Vancouver Cancer Centre, BC V5Z 4E6, Canada, 2Samuel Lunenfeld Research Institute, Toronto, Canada and 3University of British 
Columbia, Vancouver, British Columbia, Canada
Email: Minglong Zhou - mzhou@bccrc.ca; Faisal M Fadlelmola - ffadlelmola@bccancer.bc.ca; Jason B Cohn - cohn@mshri.on.ca; 
Brian Skinnider - bskinnid@bccancer.bc.ca; Randy D Gascoyne - rgascoyn@bccancer.bc.ca; Diponkar Banerjee* - diponkar.banerjee@phsa.ca
* Corresponding author    
Abstract
Background: CD30, a 120 kDa surface phosphorylated protein is a member of tumour necrosis/
nerve growth factor receptor (TNF/NGFR) family and constitutively expressed by Hodgkin and
Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL) and the neoplastic cells of Anaplastic Large
Cell Lymphoma (ALCL). A disease-specific protein marker is yet to be identified in Hodgkin
lymphoma cells. In order to define HL-specific biomarkers, novel murine monoclonal antibodies
were developed in our laboratory.
Results: Murine monoclonal antibodies (mabs) were raised against the B3 sub clone of HL-derived
cell line KM-H2. Two of these mabs (clone R23.1 mab and clone R24.1 mab) are IgG1 class
antibodies that recognize a 21 kDa protein present at the cell membrane and in the cytoplasm in
HL-derived cell lines. Clone R24.1 mab recognizes a formalin-resistant epitope and labels HRS cells
in tissue samples from patients with HL of the classical type, ALCL, and subsets of T and B cell
aggressive Non-Hodgkin Lymphomas (NHL). The antigen recognized by the clone R23.1 mab and
clone R24.1 mab does not share epitopes with CD30 cluster regions A, B, or C, and, unlike CD30,
is not expressed by phytohemagglutinin (PHA) activated T cells.
Conclusion: The 21 kDa protein detected by clone R23.1 and clone R24.1 mabs is a novel
membrane-associated protein that may be a potential marker for the diagnosis and targeted
therapy of HL and aggressive T and B cell NHL.
Background
Hodgkin and Reed-Sternberg (HRS) cells of HL and the
neoplastic cells of Anaplastic Large Cell Lymphoma
(ALCL) constitutively express CD30 [1]. CD30 has been
characterized as a 120 kDa surface phosphorylated glyco-
protein, and is a member of the tumour necrosis factor/
nerve growth factor receptor (TNF/NGFR) family [2]. Cur-
rently available antibodies against CD30 recognize one of
three clusters designated as A, B, and C. For instance, anti-
bodies Ki-2, Ki-4, Ki-5, Ki-7, Ber-H2, HRS-1 and HRS-4
recognize cluster A, antibodies Ki-1, Ki-6, and M67 recog-
nize cluster B, and antibodies Ki-3, M44, HeFi-1 and C10
recognize cluster C[3].
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an activation-associated antigen. It is expressed by acti-
vated T and B cells, HTLV-I or HTLV-II transformed T cells,
EBV-transformed B cells [4], ALCL [5], mediastinal diffuse
large B cell lymphoma [6], other diffuse large B cell lym-
phomas [7], follicular centre cell lymphoma [8], and tes-
ticular embryonal carcinoma cells [9].
The identification of cell surface molecules that are not
activation-associated markers, and have specificity for
HRS cells thus remains a desirable goal. To this end, we
have developed and characterized 2 novel monoclonal
antibodies, R23.1 and R24.1, that recognize a 21 kDa
molecule expressed by H/RS and ALCL cells, but not by
phytohemagglutinin (PHA) activated CD30+ T lym-
phocytes.
Results
Reactivity of R23.1 and R24.1 against CD30+ and CD30- 
cell lines
The two antibodies were reactive against cell surface anti-
gens of almost all CD30+ cell lines as assessed by FACS
analysis. Of 14 CD30+ cell lines, R23.1 and R24.1 labelled
12 (86%) (Table 1). Of 14 CD30 negative cell lines, none
was labelled by either R23.1 or R24.1 (Table 2). Examples
of cell surface labelling of HL cell line KMH2 by the two
antibodies as well as anti-CD30 antibody BerH2 are
shown in Figure 1. Relative antigen densities as indicated
by the position of the fluorescence peak channel tended to
vary with each antibody as well as each cell line (data not
shown).
Both antibodies labelled cytoplasmic antigens in all
Hodgkin and ALCL cell lines tested (Table 3). Examples
are shown in Figure 2. The pattern was generally diffuse in
both mononuclear and multinucleated forms of the cells,
though strong staining was observed on the cell mem-
brane. The staining pattern was similar to that observed
with the BerH2 anti-CD30 antibody.
Immunohistochemistry in tissue sections
When staining was performed using cryostat sections,
both antibodies labelled HRS cells in classical HL cases, of
both nodular sclerosis and mixed cellularity subtypes. In
lymphocyte predominance (LPHD) cases, one of two
cases contained L&H variants which were labelled by both
antibodies (data not shown). In formalin fixed sections
clone R23.1 mab was not reactive with any cells. In a series
of formalin-fixed HL and NHL cases, clone R24.1 mab
labelled none of LPHD cases, 100% of classical Hodgkin
lymphoma cases, 1 of 4 T cell-rich B cell lymphomas
(TCRBCL), 63% of diffuse large B cell lymphomas
(DLBCL), 100% of Anaplastic large cell lymphomas
(ALCL), and 80% of peripheral T cell lymphomas (PTCL),
respectively (Table 4). A survey of non-lymphoid tissue,
both benign and malignant (n = 75), including skin
melanomas, lung, colorectal, urinary bladder, and mesen-
chymal tumours revealed no reactivity to the clone R24.1
mab. Examples of positive staining in HL and ALCL clini-
cal biopsies are shown in Figure 3.
Activation of normal peripheral blood T lymphocytes
PHA activation of peripheral blood T cells resulted in the
expression of CD30 which peaked within 48 hours. CD30
were expressed by 50% of CD3+ T cells within 1 day post
simulation, peaking within 48 hours at which time point
70% of CD3+ T cells were CD30 positive, while the anti-
gens recognized by clone R24.1 mab and clone R23.1 mab
were not expressed by PHA activated CD3+ T cells even up
to 7 days post-stimulation (Figure 4). This indicates that
clone R24.1 and clone R23.1 mabs recognize epitopes/
antigens unrelated to CD30.
Table 1: Reactivity with CD30+ cell lines
Cell Line Isotype Control CD30 R23.1 R24.1
KMH2 (Hodgkin lymphoma) - + + +
HDLM (Hodgkin lymphoma) - + + +
L428 (Hodgkin lymphoma) - + + +
JB (Anaplastic large cell lymphoma) - + + +
DEL (Anaplastic large cell lymphoma) - + + +
SR786 (Anaplastic large cell lymphoma) - + + +
K562 (Erythroleukemia) - + + +
HPB/ALL (T lymphoblastic lymphoma) - + + +
OCI Ly1 (Large B cell lymphoma) - + - -
OCI Ly3 (Large B cell lymphoma) - + + +
OCI Ly19 (Large B cell lymphoma) - + - -
OCI Ly12 (Peripheral T cell lymphoma) - + + +
OCI Ly17 (Peripheral T cell lymphoma) - + + +Page 2 of 11
(page number not for citation purposes)
Molecular Cancer 2008, 7:12 http://www.molecular-cancer.com/content/7/1/12
Page 3 of 11
(page number not for citation purposes)
Table 2: Reactivity with CD30 negative cell lines
Cell Line Isotype Control BerH2 R23.1 R24.1
U937 - - - -
Jurkat (T acute lymphoblastic leukemia - - - -
HL60 - - - -
Raji (Burkitt lymphoma) - - - -
Daudi (Burkitt lymphoma) - - - -
OCI Ly7 (Large B cell lymphoma) - - - -
OCI Ly18 (Large B cell lymphoma) - - - -
OCI M2 (Erythroleukemia) - - - -
AML-2 (Acute myeloid leukemia) - - - -
AML-4 (Acute myeloid leukemia) - - - -
OCI Ly13.1 (Peripheral T cell lymphoma) - - - -
OCI Ly13.2 (Peripheral T cell lymphoma) - - - -
OCI Ly8 (B Immunoblastic lymphoma) - - - -
OCI Ly2 (Large B cell lymphoma) - - - -
FACS analysis of Hodgkin cell line KMH2 after labeling with clone R23.1, clone R24.1, or CD30 mabsigure 1
FACS analysis of Hodgkin cell line KMH2 after labeling with clone R23.1, clone R24.1, or CD30 mabs. Blue lines indicate iso-
type control binding. Solid red curves indicate mab binding.
Molecular Cancer 2008, 7:12 http://www.molecular-cancer.com/content/7/1/12Competitive binding assays
Neither clone R24.1 mab nor clone anti-R23.1 mab
blocked the ability of three different anti-CD30 antibod-
ies specific for cluster regions A, B, or C of the CD30 mol-
ecule, to bind to KMH2 cells (Figure 5). Similarly, none of
the anti-CD30 antibodies blocked the binding of clone
R23.1 mab or clone R24.1 mab to KMH2 cells (data not
shown).
Western blot analysis and immunoprecipitation
Western-blot analysis of cell lysates indicated that DEL
(ALCL), KMH2 (HL) and L-428 (HL) cells expressed a 21
kDa protein which was recognized by clone R23.1 mab
and clone R24.1 mab. The level of the 21 kDa protein was
lower in DEL than in KMH2 and L-428 cells (Figure 6).
The 21 kDa protein was immunoprecipitated by both
clone R23.1 and clone R24.1 mabs. Reciprocal probing of
the precipitated proteins by Western blot analysis indi-
cated that the clone R24.1 mab reacted with the protein
precipitated by the clone R23.1 mab and vice versa. These
results indicate that clone R23.1 and clone R24.1 mabs
reacted with the same 21 kDa protein in DEL, KMH2 and
L-428 cells (Figure 7).
Discussion
CD30, a 120 kDa surface phosphorylated glycoprotein
[10], is a marker of activation of T and B lymphocytes [11-
15] but because of its constitutive overexpression in clas-
sical Hodgkin lymphoma, it is widely used for diagnostic
purposes [1,16-18]. It is well known that CD30 expression
is not unique to Hodgkin lymphoma, as it is expressed in
Anaplastic Large Cell Lymphoma (ALCL)[19], mediasti-
nal large B cell lymphoma [6,20], a subset of nodal diffuse
large cell lymphoma[21], large cells in follicular lym-
phoma [22], nodal and cutaneous diffuse large B cell lym-
phoma [23-28], peripheral T cell lymphoma [29-32],
embryonal carcinoma and other non-lymphoid cells and
neoplasms [9,33-37].
With the intention of developing additional antibodies
with specificity for non-activation markers of Hodgkin
lymphoma, we have characterized 2 novel antibodies that
detect a protein constitutively overexpressed in Hodgkin
lymphoma. One of the two antibodies, clone R24.1 mab,
recognises a formalin-resistant epitope. Although the spe-
cificity of the 2 antibodies initially raised the possibility
that they are directed against CD30, subsequent experi-
ments proved otherwise. Two B cell lymphoma cell lines
(OCI Ly1 and OCI Ly19, Table 1) which are CD30+ lack
both R23.1 and R24.1 antigen expression. Unlike CD30,
R24.1 antigen expression is not seen in non-lymphoid
malignancies, and differences of expression are noted in
CD30 negative T cell rich B cell lymphomas, diffuse large
B cell lymphomas and peripheral T cell lymphomas, indi-
cating heterogeneity of expression (Table 4). The R23.1
and R24.1 antigen expression is not activation-induced,
unlike CD30. Whereas CD30 surface expression by nor-
mal T cells peaked within 48 hours after PHA stimulation,
neither R23.1 antigen nor R24.1 antigen was expressed on
the cell surface by PHA-stimulated T cells. Clone R23.1
and clone R24.1 mabs did not compete with any of the
anti-CD30 antibodies directed against the A, B and C
extracellular domains of CD30. Western blots and immu-
noprecipitation studies established that clone R23.1 and
clone R24.1 mabs recognize a 21 kDa molecule, which is
KMH2 cells labelled with clone R24.1 mabFigure 2
KMH2 cells labelled with clone R24.1 mab. Both membrane 
and cytoplasmic staining was observed. Magnification ×400.
Table 3: Cytoplasmic immunostaining in Hodgkin lymphoma and anaplastic large celllymphoma cell lines
Cell Line Isotype Control Ber-H2 R24.1 R23.1
KMH2 (Hodgkin lymphoma) - + + +
L428 (Hodgkin lymphoma) - + + +
HDLM-2 (Hodgkin lymphoma) - + + +
DEL (Anaplastic large cell lymphoma) - + + +
JB (Anaplastic large cell lymphoma) - + + +
SR786 (Anaplastic large cell lymphoma) - + + +Page 4 of 11
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tein CD30 [2]. We are in the process of determining the
identity of the 21 kDa protein by mass spectrometry and
its encoding gene by expression cloning.
A non-activation induced cell surface protein expressed in
Hodgkin lymphoma and aggressive non-Hodgkin lym-
phomas may have immunotherapeutic potential as anti-
bodies that target such a molecule are less likely to be toxic
to normal activated immune cells. Anti-CD30 immuno-
therapy is being explored in pre-clinical models and a few
human clinical trials have been conducted, but toxicity
has been a problem [38-52] and the long-term sequelae
are not yet known. Novel immunotherapy targets and
antibodies still require exploration. We are currently eval-
uating the cytotoxic effects of the two antibodies against
HL cell lines in vitro and in vivo HL xenograft models of
Hodgkin lymphoma. Tissue microarrays are being assem-
bled from large numbers of Hodgkin lymphoma, diffuse
large T and B cell lymphoma, and Anaplastic Large Cell
Lymphoma clinical specimens from patients with long-
term follow-up in order to determine whether the 21 kDa
protein expression has any prognostic significance.
Conclusion
Clone R23.1 and clone R24.1 mabs recognize a novel 21
kDa cell surface and cytoplasmic protein in HL and ALCL
cells as indicated by immunoprecipitation and Western-
Table 4: Expression of antigens by neoplastic cells in paraffin sections of clinical biopsysamples
Type Number CD30 (% Positive) R24.1(% Positive)
NLPHD 5 0 (0) 0 (0)
NSHD 21 21 (100) 21 (100)
MCHD 10 10 (100) 10 (100)
LDHD 2 2 (100) 2 (100)
TCRBCL 4 0 (0) 1 (25)
DLBCL 8 4 (50) 5 (63)
ALCL 8 8 (100) 8 (100)
PTCL 5 3 (60) 4 (80)
Total 63 48 (76) 51 (81)
NLPHD = Nodular lymphocyte predominance Hodgkin's disease; NSHD = Nodular sclerosis Hodgkin's disease; MCHD = Mixed cellularity 
Hodgkin's disease; LDHD = Lymphocyte depletion Hodgkin's disease; TCRBCL = T cell rich B cell lymphoma; DLBCL = Diffuse large B cell 
lymphoma; ALCL = Anaplastic large cell lymphoma; PTCL = Peripheral T cell lymphoma
Tissue sections from clinical Biopsies labelled with clone R24.1 mabF g re 3
Tissue sections from clinical Biopsies labelled with clone R24.1 mab. On the left panel, a HL tissue section shows intense stain-
ing with a membrane and Golgi pattern. On the right panel, an ALCL tissue section shows intense staining of neoplastic ALCL 
cells. Magnification ×400.Page 5 of 11
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epitope and labels HL, ALCL, and other aggressive forms
of NHL. The epitopes R23.1 and R24.1 may potentially be
used as a therapeutic target for HL, ALCL and other sub-
sets of NHL. The clone R24.1 mab could be used in
patient-selection for such therapies.
Methods
Animal care and experiments were carried out in accord-
ance with the guidelines of the Canadian Council on Ani-
mal Care and all protocols were approved by the Animal
Care Committee of the University of Toronto.
Research (immunohistochemistry) was carried out on
archived paraffin blocks from clinical biopsies. The use of
the archived paraffin tissue was approved by the Univer-
sity of British Columbia Clinical Research Ethics Board in
compliance with the Helsinki Declaration (Approval Cer-
tificate number H06-60016).
Preparation of anti-KM-H2 monoclonal antibodies
Animal care and experiments were carried out in accord-
ance with the guidelines of the Canadian Council on Ani-
mal Care and all protocols were approved by the Animal
Care Committee.
BALB/c mice were immunized with 2 × 108 live KMH2 B3
cells (a sub-clone of Hodgkin lymphoma cell line KM-
H2), by intraperitoneal injection. Fourteen days later, the
mice received intraperitoneal injections of 4 × 107 live
KM-H2 B3 cells. On day 24, 100 µL of blood was collected
from each mouse and the serum was screened for anti-
KM-H2 antibodies by FACS analysis (FACSort; Becton
Dickinson, Mississauga, ON, Canada). Sera from all five
mice contained antibodies that bound to KMH2 cells,
whereas sera from unimmunized control mice had no
detectable anti-KMH2 antibodies. On day 33, the mice
were given intraperitoneal injections of 106 live KMH2
cells. Serum was collected and screened for anti KMH2
binding activity by FACS analysis. The mouse with the
highest titer of KMH2 binding activity was boosted by
intravenous injection of 106 live KM-H2 cells on day 91.
Five days later, the mouse was sacrificed humanely and
the spleen was harvested aseptically. Spleen cells were
fused with hypoxanthine guanine phosphoribosyl trans-
ferase (HGPRT) deficient P3X63-AG8.653 [53] mouse
myeloma cells (non-secretor) in a 5:1 ratio of spleen cells
to myeloma cells. Fused cells were selected in hypoxan-
thine, aminopterin and thymidine (HAT) medium using
a final working concentration as follows: 100 µM hypox-
anthine, 0.4 µM aminopterin, 16 µM thymidine (Sigma-
Aldrich Canada Ltd.; Oakville, ON, Canada) [53]. Hybri-
doma supernatants were screened for IgG and IgM pro-
duction by ELISA. Six IgM and 10 IgG producers were
identified. Supernatants from the 10 IgG producers were
screened by FACS analysis for anti-KMH2 antibodies and
5 of the 10 were found to be producing such antibodies.
These were cloned twice by limiting dilution and the
supernatants were re-screened by FACS for anti-KM-H2
Competitive binding assayFigur  5
Competitive binding assay. Clone R24.1 and clone R23.1 
mabs did not block the binding of anti-CD30 (BerH2 anti-
body) to KMH2 cells.
PHA stimulation of T cellsFigure 4
PHA stimulation of T cells. T cells exposed to PHA 
expressed CD30 within 24 hours, peaking at 48 hours. 
Expression of R23.1 and R24.1 remained at control levels 
even up to 7 days after PHA stimulation, indicating that acti-
vation of T cells does not induce expression of R23.1 and 
R24.1 antigens, unlike CD30.Page 6 of 11
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Western-blot analysis of DEL, KMH2 and L-428 cell lysatesFigure 6
Western-blot analysis of DEL, KMH2 and L-428 cell lysates. A protein with a mass of 21 KDa was detected by clone R23.1 (A) 
and clone R24.1 (B) mabs in the cell lysates. Lane 1 contains molecular weights and lanes 2–4 contain cell lysates of DEL, KMH2 
and L-428 respectively.
Immunoprecipitation and Western-blot analysis of DEL, KMH2 and L-428 cell lysatesFigure 7
Immunoprecipitation and Western-blot analysis of DEL, KMH2 and L-428 cell lysates. 23.1 (Panel A and C) and R24.1 (Panel B 
and D). Samples were separated on 4–20% Life-gel and transferred onto nitrocellulose membranes. The membranes were then 
blocked in 5% non-fat dry milk and probed with monoclonal antibody clones R23.1 (Panel A and B) and R24.1 (Panel C and D) 
followed by goat-anti-mouse IgG-AP. The membranes were developed in BCIP/NBT. A protein band of ~21 KDa as well as IgG 
light chain were detected in all three lysates examined. Lane 1 contains molecular weights and lanes 2–4 contain Immunopre-
cipitated samples of DEL, KMH2 and L-428.
Molecular Cancer 2008, 7:12 http://www.molecular-cancer.com/content/7/1/12activity. Two clones were selected for further analysis
(R23.1 and R24.1).
Cell lines and cell culture
Cell lines were grown in Iscove's Modified Dulbecco's
Medium (IMDM) supplemented with penicillin and
streptomycin, 1% Fungizone (Gibco/BRL, Gaithersburg,
MD, USA), and 10% fetal bovine serum (FBS) (Invitro-
gen, Burlington, ON, Canada). Hodgkin lymphoma (HL)
cell lines, KMH2 and L-428, and anaplastic large cell lym-
phoma (ALCL) cell line Del were purchased from DSMZ
(Braunschweig, Germany). The cell lines HPB/ALL (T-cell
lymphoblastic non-Hodgkin's Lymphoma), K562 (Eryth-
roleukemia), U937 (Monocytic leukemia), HL60 (promy-
elocytic leukemia), DAUDI (Burkitt's lymphoma), MOLT-
4 (T-cell Lymphoblastic leukemia), and Jurkat (Acute T-
cell leukemia) were purchased from the American Type
Culture Collection (ATCC). OCI Ly1, Ly2, Ly3, Ly7, Ly18,
Ly19 (Large B-cell Non-Hodgkin's Lymphomas); OCI Ly8
(B-immunoblastic lymphoma); OCI Ly12, Ly13.1, Ly13.2
and Ly17 (T-cell Non-Hodgkin's Lymphomas); OCI-M2
(Erythroleukemia); AML-2 and AML-4 (Acute Myeloid
Leukemia) were all generous gifts from Dr. Hans Messner
(Ontario Cancer Institute/Princess Margaret Hospital,
University Health Network, Toronto, ON, Canada).
Determination of cell surface expression of antigens on 
cell lines
Cells were washed (4 min.; 300 × g) two times in calcium
and magnesium-free phosphate buffered saline (PBS-)
and then treated as follows to block non-specific binding
of mabs. Cells undergoing direct staining were blocked
with 10 µg of pure mouse IgG (Sigma, Oakville, ON, Can-
ada) for 20 minutes at 4°C. Cells undergoing indirect
staining were blocked with 10% normal goat serum
(NGS) for 20 minutes at 4°C. Cells were then washed in
PBS-. Cell concentrations were adjusted so each tube
received 1 × 106 cells. CD30-FITC (Dako, Mississauga,
ON, Canada) was added at 1 µg per tube, the two mabs
were added at 1 µg per tube, the mouse IgG1 isotype con-
trols (IgG1-FITC and mouse IgG unconjugated) were both
added at 1 µg per tube. Primary antibody staining was
done for 30 minutes at 4°C in the dark. Cells were then
washed in PBS-, and goat anti-mouse IgG -PE (Dako) was
added and allowed to incubate for 30 minutes at 4°C in
the dark. Viability was assayed by propidium iodide exclu-
sion. Cells were washed in PBS- and 300 µl of fixative (1%
paraformaldehyde) was added. Cells were analyzed on a
FACSort flow cytometer (Becton Dickinson) within 15
minutes.
Immunocytochemistry and immunohistochemistry
Immunocytochemistry was performed using monoclonal
antibody BerH2 (Dako), and the 3 monoclonal antibod-
ies. Cytospins were prepared using the cell lines KMH2,
L428, HDLM-2, JB, DEL, and SR786, as follows. Cells were
washed 1× PBS- and centrifuged for 4 min. at 300 × g. Cells
were then added to a 20% FBS/PBS- solution and 25 µl
aliquots of this solution was added to 100 µl of PBS- and
spun for 5 min. at 50 × g (Cytospin 2; Shandon). Slides
were allowed to air dry overnight.
Identical sets of slides were fixed in 2% paraformaldehyde
at room temperature (RT) or cold acetone (4°C) for 10
minutes. Slides were then washed in PBS-. Slides were
blocked in 10% normal goat serum (NGS) diluted in anti-
body dilution buffer (Dako) for 20 min. at RT. The slides
were then washed in PBS and stained with the primary
antibody for one hour (diluted in antibody dilution
buffer as above) in the following concentrations: R23.1
and R24.1, at 16 µg/ml; CD30 at 8 µg/ml; Isotype control
at 16 µg/ml (in antibody dilution buffer). Slides were
washed in PBS and incubated with 1/200 dilution of
biotinylated goat anti-mouse IgG (Zymed, South San
Francisco, CA, USA) for 20 minutes, washed in PBS, and
then stained with 1/4 dilution of streptavidin-biotin com-
plex labelled with horseradish peroxidase for 20 min.
(Ultra Streptavidin Detection System; Signet). The
enzyme reaction was developed with AEC (3-amino-9-
ethyl carbazole) and counterstained with hematoxylin.
Immunohistochemistry was carried out on deparaffinized
tissue sections (5 micron thickness). Endogenous peroxi-
dase was quenched by treating the sections with 3%
hydrogen peroxide for 10 minutes, followed by rinsing in
PBS. Antigen retrieval was done by pepsin digestion
(0.4% pepsin for 3 minutes, then rinsing in PBS-) prior to
labelling. Non-specific binding was blocked with 10%
human AB serum for 20 minutes at room temperature.
R24.1 hybridoma supernatant was used at 1/4 dilution
whereas purified R24.1 was used at 16 µg/ml. The slides
were incubated at room temperature for 60 minutes,
rinsed in PBS and then incubated with biotinylated goat
anti mouse IgG (Zymed) at 1/200 at room temperature for
20 minutes, followed by rinsing in PBS. They were then
incubated for 20 minutes in 1/4 dilution of streptavidin-
biotin complex labelled with horseradish peroxidase for
20 min. (Ultra Streptavidin Detection System; Signet).
After rinsing in PBS-, the slides were incubated with AEC
for 10 to 20 minutes, rinsed in PBS- and counterstained
with Mayer's hematoxylin.
Chemicals and reagents
IMDM media was purchased from StemCell Technologies
Inc. (Vancouver, Canada). Protein G-sepharose beads
were purchased from Sigma (St. Louis, Mo, USA). Fungi-
zone was purchased from Gibco (Grand Island, NY, USA).
Proteinase inhibitor cocktail, 30% polyacrylamide (acry-
lamide: bis = 29:1) and substrate BCIP/NBT were pur-
chased from Sigma (St. Louis, MO, USA). Seize ClassicPage 8 of 11
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from Pierce biotechnology (Rockford, IL, USA).
Other antibodies
Monoclonal Anti-CD30 was purchased from BD
Pharmingen (San Diego, CA, USA). Secondary antibody,
goat anti-mouse IgG Alkaline phosphatase, was pur-
chased from Sigma (St. Louis, MO, USA).
Lysate preparation
Lysis buffer (RIPA) [54] was added to the cell pellets at
10:1 (V/W) ratio and the samples were then incubated on
ice for 10 minutes. The debris was removed by centrifug-
ing at 10000 g for 10 min. Proteinase inhibitor cocktails
(Sigma, MO, USA) were added to lysis buffer to reduce the
degradation.
SDS-PAGE and Western-blot analysis
The protein samples were analysed on 4–20% gradient gel
(Life Gels, Life Therapeutics, Clarkston, GA). The gels
were run at 140 V for 70 min. After the proteins were
resolved by SDS-PAGE, the gels were incubated in 1 ×
transfer buffer [54] for 30–60 min. Separated proteins
were transferred onto nitrocellulose membrane (Milli-
pore, Billerica, MA, USA) with semi-dry-Transfer appara-
tus (BioRad, Hercules, CA, USA). After the nitro-cellulose
membranes were blocked in 2% BSA-PBS (pH 7.2) for 2
hours at room temperature, they were probed with pri-
mary and secondary antibodies sequentially at 4°C over-
night and for 2 hrs at room temperature followed by 4
washes in PBS. The primary antibodies were diluted clone
R23.1 mab, clone R24.1 mab and anti-CD30, and the sec-
ondary antibody was goat anti-mouse IgG alkaline phos-
phatase. The protein bands were finally visualized in
BCIP/NBT substrate (Sigma, MO, USA).
Immunoprecipitation
Immunoprecipitation was performed using protein-A
beads from Sigma (St. Louis, MO, USA). Briefly, 400 µl of
cell lysates were precleared for 2 hrs at 4°C with 100 µl of
50% protein-A beads absorbed with normal mouse IgG.
The precleared lysates were then incubated overnight with
100 µl of protein-A-antibody beads at 4°C. The beads
were centrifuged at 10,000 g for 1 min and washed 4 times
with 1.5 ml of PBS (pH 7.2). The washed beads were
boiled for 10 min in 100 µl of SDS-sample buffer and the
samples were analyzed by SDS-PAGE and Western-blot
analysis.
Alternatively, the samples were eluted from the beads in 8
× 400 µl of glycine (0.01 M, pH2.8). The eluted samples
were pooled and neutralized with 1 M Tris (pH7.4) and
concentrated with Microcon YM-10 (Millipore, Billerica,
MA, USA).
Activation of normal peripheral blood T lymphocytes
Peripheral blood from healthy volunteers, who provided
written informed consent, was obtained by venipuncture.
Lymphocytes were isolated by density gradient centrifuga-
tion using Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden), washed twice in PBS- and then cultured in
IMDM supplemented with penicillin, streptomycin, 1%
Fungizone (Gibco/BRL), 10% FBS and 100 µg/ml of phy-
tohemagglutinin-M (PHA-M). Cells were analyzed at 0,
24, 48, 72, 96, 120, 144, and 168 hours after initiation of
culture. Analysis was based on viable (Propidium iodide
negative) CD3+ cells co-expressing CD30, R23.1, or
R24.1.
Competitive binding assays
KMH2 cells were harvested and washed twice in PBS- (300
× g; 4 min.). Cells were blocked in 20 µg/ml of total
mouse IgG (Sigma; I-5381) for 45 min. at 4°C. Cells were
then washed twice in PBS- (300 × g; 4 min.) and resus-
pended in PBS-. Antibodies were added in a cocktail
approach (unconjugated plus conjugated) to tubes (12 ×
75 mm, 5 ml polystyrene; Falcon 35-2008). Unconju-
gated antibodies were added to a fixed (0.1 µg/ml) conju-
gated amount. Varied amounts (0 to 0.3 µg/ml) of
unconjugated anti-CD30 antibody BerH2 (Dako), R23.1,
or R24.1 were mixed with fixed amounts of FITC-conju-
gated anti-CD30 antibodies BerH2 (Dako; M0751), phy-
coerythrin conjugated AC10 (Ancell; 179-020), FITC-
conjugated R23.1, or R24.1. Ki-1 was not available as a
conjugated antibody, thus CD30 clone Ki-1 unconjugated
(Immunotech) was mixed with fixed amounts (0.1 µg/
ml) of FITC-conjugated R23.1 or R24.1 antibodies. Mouse
IgG-FITC/or R-PE (Immunotech) was used as isotype con-
trol as relevant. One × 105 cells were added to each tube,
mixed gently, and allowed to stain for 25 min. at 4°C.
Labelled cells were washed once, incubated with 0.5 µg of
propidium iodide (Pharmingen), washed, and then fixed
in 1% paraformaldehyde and analyzed on a FACSort (Bec-
ton Dickinson). Cells were gated for viable cells by exclud-
ing those positive for propidium iodide.
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